Stock Detail
CATALYST PHARMACEUTICAL PARTNERS INC
Drugs - Generic
CPRX @ Yahoo Finance | CPRX Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $1.01 | $1.05 | $0.00 | 0.00% | 0.00 | $1.01 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $1.04 | $1.00 | 89,724 | 21.87M | 87,179.5 | -4.39 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 1.07 | 1.04 | 1.02 | 0.99 | 0.97 |
Stock Profile
Catalyst Pharmaceutical Partners, Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs for the treatment of drug addiction. The company is developing CPP-109, which is based on the chemical compound gamma-vinyl-GABA for the treatment of addiction to cocaine, methamphetamine, and other addictive substances. It also intends to develop CPP-109 to treat other addictions, such as addictions to nicotine, prescription pain medications, alcohol, and marijuana, as well as treatments for obsessive-compulsive disorders, including obesity and compulsive gambling. In addition, Catalyst Pharmaceutical Partners, through a worldwide license agreement with Brookhaven National Laboratory, owns interest primarily in nine patents relating to the right to use vigabatrin to treat various substance addictions. The company was founded in 2002 and is based in Coral Gables, Florida.